Emerson Electric Co. (NYSE: EMR) — A 70-Year Conglomerate Reborn as a Pure-Play Automation Bet, Priced at Its Richest Multiple Ever

Independent fundamental research and general information — not investment advice. A position is taken only in the clearly-labeled “Claude’s Take” block below; the analysis that follows it (sections 1–15) is deliberately position-free and carries no price target.

Report date: 2026-06-19 · Price (6/18/26): $150.66 · Market cap: ~$84.8B · Enterprise value: ~$96.4B · Fiscal year-end: September 30

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information — not investment advice. The analysis that follows (sections 1–15) takes no position and carries no price target.

Verdict: HOLD / AVOID-here for new capital; not-a-short; accumulate-on-weakness toward ~$115–125 (≈18x forward adjusted EPS / ≈4x EV-sales). Medium conviction.

Emerson has executed one of the cleaner large-cap portfolio transformations of the cycle: it sold its cyclical, lower-multiple Climate/Copeland and InSinkErator businesses near the top, plowed the proceeds into automation software and test-and-measurement (National Instruments, then the AspenTech take-private), and re-emerged as a focused process-and-industrial-automation company with a 52.8% gross margin, ~28% adjusted segment EBITDA margins, ~18% free-cash-flow margins, and a genuine, narrow-but-deep moat in distributed control systems (DeltaV/Ovation) where the installed base runs refineries and power plants for 20–30 years. The market has rewarded this with a re-rating that is, by Emerson’s own multi-year history, the richest the stock has ever been on sales (≈99th percentile) and near the richest on earnings (≈95th percentile) — ~5.3x EV/sales, ~19x EV/EBITDA, ~23x forward adjusted EPS, against a business that still grows revenue at low-single to mid-single digits organically and earns an all-in cash ROIC of only ~10–11% on its post-acquisition capital base.

That is the whole tension. The bull pays for the mix (more software, recurring ACV growing 10%+, power/LNG/datacenter/life-sciences secular verticals up 22%) and bets the re-rating is structural. The skeptic notes that (1) the headline you are paying 23x for is adjusted EPS that excludes >$1B/yr of amortization on the $16B+ Emerson spent on NI and AspenTech — the same metric management’s bonus and long-term incentive are paid on, so GAAP EPS is ~$4 and GAAP ROE is ~5.6%; (2) the cross-read says Emerson has always been the low-multiple “de-rate anchor” of the multi-industrial group for structural reasons — slow organic, ~10–13% ROIC — so “richest-ever versus itself” is doing a lot of work; (3) insiders bought zero shares in the open market across 29 months and the CEO sold ~$10.8M discretionarily (not 10b5-1) into the run; and (4) the dividend, while a 69-year “King,” now grows ~0.5–1%/yr and buybacks barely offset dilution. The framing from the tape supports caution-not-shorting: beta ~1.26, a negative low-volatility loading, a strong dividend-yield loading, no value loading, and a +22%/yr three-year run at a 0.71 Sharpe — a high-quality cyclical that has already had its move, not a falling knife and not a coiled spring. Conviction: medium. Flips bullish on a 15–20% drawdown that resets the multiple toward ~4x EV/sales while ACV/software keeps compounding double-digit and orders stay positive; flips bearish on a process-capex air-pocket (China chemical glut + a stalled power/LNG funnel) or evidence that AI compresses, rather than expands, the value of the industrial-software seats Emerson just paid a premium to own. Tag: bought the right business, at the wrong price, paid for in adjusted earnings.

📈 Stock Price Action — Five-Year Event Map

Over five years Emerson round-tripped from the high-$80s (mid-2021), bottomed at $67.93 on 27-Sep-2022 in the rate-shock bear market just as the portfolio overhaul was being announced, then more than doubled to an all-time high of $160.42 on 10-Feb-2026 as the “pure-play automation” re-rate took hold. It now trades at $150.66, ~6% off that high, above its 21-/50-/200-day EMAs (≈$142/$140/$136), with a 52-week range of $122.75–$160.42. The arc is a transformation re-rating, not an earnings melt-up: revenue and adjusted EPS roughly doubled the multiple did the rest.

Cycle narrative. (1–2) Emerson entered the period as a classic slow-organic multi-industrial and de-rated with the 2022 bear market, bottoming near $68 as management announced the most aggressive reshape in its history. (3) The $14B Climate/Copeland sale to Blackstone and the agreement to buy National Instruments converted the story to “automation pure-play,” driving a 37% recovery. (4) 2024 layered on the electrification/AI-power capex theme — power orders surging, the project funnel building — taking the stock to ~$121. (5) Early 2025’s pullback paired the debt-funded AspenTech minority buy-in with tariff and China-chemical worries. (6) The dominant leg: a year-long ~50% re-rate into Feb-2026’s $160 all-time high, paying up for the software/recurring mix and the secular verticals. (7) The recent ~6% fade reflects the Q2-FY26 Middle East disruption (a 1-point sales hit, ~$50M in-quarter), persistent China chemical weakness, and a pause after a very large move — DA Davidson initiated Neutral (6/16/26) and Bernstein Outperform (6/10/26), bracketing the debate. Price moves are Fact; attributed causes are Interpretation.

1. Executive Summary

Emerson Electric is a ~$18B-revenue, ~$85B-market-cap global leader in process and industrial automation — the sensors, valves, controllers, distributed control systems (DCS), and industrial software that run continuous and hybrid process plants (refining, chemicals, LNG, power, life sciences, metals/mining, water). After a four-year “Project Beyond” reshape, Emerson is no longer the sprawling conglomerate that also made compressors, garbage disposals, and HVAC components. It sold those businesses — InSinkErator to Whirlpool ($3.0B, 2022) and Climate Technologies/Copeland to Blackstone ($14.0B enterprise value, 2023, fully exited 2024) — and redeployed into automation: it bought National Instruments ($8.2B equity, 2023, now “Test & Measurement”) and consolidated and then took private the ~43% minority of AspenTech ($7.2B at $265/share, March 2025), building an industrial-software franchise around AspenTech, Ovation, DeltaV, and NI.

The financial profile that emerges is genuinely better than the old Emerson: gross margin 52.8% (FY2025, up from ~42% in FY2020), adjusted segment EBITDA margin ~28%, reported free cash flow ~$3.2B (18% of sales) on light ~2.4%-of-sales capex, and an installed base that generates ~65% maintenance/MRO revenue with very high switching costs. Orders are positive (+5% underlying in Q2-FY26), backlog is $8.2B (+9% y/y), software annual contract value (ACV) is $1.64B growing ~9–10%, and the project funnel is a record $11.2B driven by secular “growth verticals” — power, LNG, life sciences, semiconductors, and aerospace/defense — up 22% collectively.

The problem is price. On its own multi-year history, Emerson has never been more expensive on sales (P/S ~99th percentile, ~5.3x EV/sales) and is near its richest on earnings (P/E ~95th percentile; ~23x forward adjusted EPS of ~$6.50, ~37x trailing GAAP EPS of ~$4). The re-rating capitalizes a higher-margin, software-richer mix as permanent at the same moment that (a) organic growth is still only low-to-mid single digits, (b) all-in cash ROIC on the post-deal capital base is ~10–11% — barely above cost of capital — because Emerson paid premium multiples for NI and AspenTech, © the headline EPS everyone quotes excludes >$1B/yr of acquisition amortization that is the real cost of that strategy, and (d) insiders have bought nothing and sold discretionarily into the move. Emerson has historically been the low-multiple “de-rate anchor” of the multi-industrial cohort; it now sits at the top of its own valuation range while still screening cheaper than Eaton, Parker, or Ametek.

The investment question is not whether Emerson is a good business — it is — but whether ~5x sales and ~23x adjusted earnings correctly price a low-to-mid-single-digit organic grower with a ~10–11% all-in return on capital, or whether the market has extrapolated a software/secular re-rating that the unit economics do not yet justify. This memo argues the business quality is real and the moat in process DCS is durable, but the valuation embeds an optimistic, hard-to-falsify “structural re-rate” that leaves little margin of safety and a poor risk/reward for new capital at the current price.

2. Business Overview

Emerson sells the hardware and software that measure, control, and optimize industrial processes. Its customers are the operators of continuous and batch process plants — energy (refining, oil & gas, LNG), chemicals, power generation and grid, life sciences/pharma, metals & mining, pulp & paper, food & beverage, water/wastewater, and increasingly semiconductors and data centers. The value proposition is uptime, safety, throughput, yield, and energy/emissions efficiency on assets that cost billions and run continuously for decades; the cost of a measurement or control failure (an unplanned shutdown, an off-spec batch, a safety incident) dwarfs the cost of Emerson’s content, which is why the installed base is sticky and aftermarket-rich.

Reporting structure (FY2025). Emerson reports two business groups across six segments:

Source: FY2025 10-K (emr-20250930). Group “Software & Control” replaced the former standalone AspenTech segment after the March-2025 take-private; prior periods restated.

Two structural facts jump out. First, Software & Control carries a 14.5% GAAP EBIT margin but a ~31% adjusted EBITA margin — a >2x gap that is entirely purchase-accounting amortization of the NI and AspenTech intangibles. Test & Measurement (NI) is still GAAP-loss-making at the segment line (−$68M FY2025, improved from −$290M FY2024) because $425M+ of NI amortization runs through it. This is the quality-of-earnings crux of the whole story. Second, Intelligent Devices (69% of sales) is the cash engine — Final Control and Measurement & Analytical are high-20s-margin, installed-base, aftermarket-rich franchises; they are the real moat. Software & Control is the growth/mix story the multiple is paying for.

Revenue model. Roughly 65% of sales are MRO (maintenance, repair, operations — recurring spend tied to the installed base) and ~35% are project/KOB (“kind of business” greenfield and brownfield capital projects). Software annual contract value (ACV) — the recurring subscription/term base across AspenTech and NI — is $1.64B and growing ~9–10%, a genuinely recurring, high-incremental-margin layer. Price contributed ~3.5 points to growth in Q2-FY26, evidence of real pricing power. Geographically, FY2025 was ~51% Americas, ~30% Asia/Middle East & Africa (China ~10%), ~19% Europe.

Verdict. A high-quality, installed-base-anchored automation franchise with a recurring-revenue spine, genuine pricing power, and a software-mix upgrade in progress. The economics are real; the GAAP statements understate the cash earnings but also flatter the returns on the capital deployed to build the software layer. This is a good business — the debate is entirely about what it is worth.

3. Industry Dynamics

The process-automation industry is structurally attractive in its core and competitively brutal at its edges — and Emerson, post-reshape, sits heavily in the attractive core.

Market structure — the DCS oligopoly. The heart of process automation is the distributed control system (DCS) and the surrounding instrumentation (pressure/temperature/flow/level sensors, control and isolation valves, analyzers). The global DCS market is a stable oligopoly: Emerson (DeltaV for process, Ovation for power/water), Honeywell (Experion), Siemens, ABB, Yokogawa, and Schneider Electric (Foxboro/AVEVA) control the vast majority of installed systems. This is one of the better industry structures in all of industrials, for three reasons:

1. Switching costs are extreme. A DCS runs a refinery, chemical plant, or power station for 20–30 years. Ripping one out means re-engineering control logic, re-certifying safety systems, retraining operators, and — worst — risking downtime on an asset that earns millions per day. Operators almost never switch platforms mid-life; they expand and modernize on the incumbent. This produces decades-long annuity revenue (MRO, upgrades, services) per installed system.
2. Entry barriers are qualification-based, not just capital-based. New entrants must clear functional-safety certifications (IEC 61508/61511), industry approvals, reference installations, and — critically — earn the trust of plant operators who will not bet uptime on an unproven vendor. There has been no successful new global DCS entrant in decades.
3. The aftermarket is the profit pool. Like aerospace, the razor (the initial system/instrument sale) is less profitable than the blades (spares, services, software, modernization across a multi-decade life). Incumbency compounds.

The cyclical overlay. Demand is tied to process-industry capital spending, which is cyclical and tied to commodity/energy prices and global GDP. The current cycle has a favorable secular overlay — Emerson’s five “growth verticals”: power (grid modernization, behind-the-meter generation for data centers, nuclear life-extension), LNG (export capacity build-out), life sciences (GLP-1 capacity, biologics), semiconductors (fab build-out, test), and aerospace/defense. Management sizes the project funnel at a record $11.2B with 85% in these verticals, and power orders (Ovation) were up 41% in Q2-FY26. This is real and is the single best argument for the re-rating. But it must be weighed against (a) China’s chemical sector in deep overcapacity (Emerson’s China revenue guided down mid-single-digits), (b) European process markets soft, and © the Marathon capital-cycle caution: secular-demand narratives at a multi-year valuation peak are exactly when supply and competition respond.

Software as the new battleground. AspenTech (process optimization, asset performance management, digital grid management) and NI (test & measurement) move Emerson up the stack into higher-margin, recurring industrial software — the same prize Siemens (with its Xcelerator/MindSphere stack), Schneider/AVEVA, and Honeywell are chasing. The bull case is that Emerson uniquely couples this software with the largest process installed base. The bear case is that industrial software is a crowded, slower-monetizing land-grab and that Emerson paid a peak SaaS multiple for AspenTech to win it.

Verdict: structurally good industry in the core (DCS/instrumentation oligopoly, high switching costs, aftermarket annuity), with a cyclical-capex overlay and a more contested, lower-return software frontier. Emerson is well-positioned in the good part. The industry quality is not in doubt; the question is cyclical timing and price.

4. Competitive Position

The moat is real, narrow, and deep — concentrated in process DCS and final-control/measurement, thinner in discrete and software. In Greenwald’s taxonomy, Emerson’s core advantage is customer captivity (switching costs) reinforced by economies of scale in a specific niche — not a wide, pervasive moat across everything it sells.

Where the moat is strongest — Final Control and Measurement & Analytical (Intelligent Devices, 69% of sales, high-20s% margins). Emerson’s Fisher control valves, Rosemount instrumentation, and the DeltaV/Ovation control systems are category leaders with #1 or #2 global share in their niches. The captivity mechanism is textbook: once a plant is engineered around Fisher valves and Rosemount transmitters wired into a DeltaV system, the spares, calibration, services, and modernization flow to Emerson for the asset’s life. The financial fingerprint of this moat is the 52.8% gross margin, ~26%+ segment EBIT margins, ~65% MRO revenue, and pricing power (+3.5 pts in a soft quarter) — outcomes that would deteriorate quickly if the captivity were not real. This is the part of Emerson worth a premium.

Greenwald tests. (1) Market-share stability: the DCS/instrumentation oligopoly has been remarkably stable for decades — incumbents hold position; no new global entrant. Pass. (2) ROIC test: here the verdict is nuanced. The operating businesses earn high-teens-to-20s returns on tangible capital (light capex, high margins). But all-in cash ROIC on the post-acquisition capital base is only ~10–11% (adjusted NOPAT ~$3.6B on ~$32B invested capital including the NI/AspenTech goodwill) — because Emerson paid full price to assemble the software layer. So the legacy business clears the ROIC test handily; the acquired growth was bought at roughly cost of capital. This is the central reason the moat, while real, does not yet justify the multiple.

Direct competition.

• Honeywell — the closest peer; Experion DCS vs. DeltaV, plus instrumentation and a process-software stack. Honeywell is itself splitting up and its own analysis frames Emerson as the comparable “process-automation pure-play.”
• Siemens / ABB / Schneider (AVEVA) / Yokogawa — global DCS and instrumentation competitors, each with its own software ambitions. Schneider’s AVEVA and Siemens’ Xcelerator are the most direct industrial-software threats to AspenTech.
• Rockwell Automation — more discrete/factory automation (PLCs), less process; a partial overlap in Discrete Automation, where Emerson is weaker (18.6% margin, the lowest segment).
• In Test & Measurement (NI): Keysight, Rohde & Schwarz, Teradyne, Advantest — a competitive, cyclical instrument market where Emerson is a #2-ish player it bought, not a dominant one (and where NI is still GAAP-loss-making after amortization).

Where the moat is thin. Discrete Automation (commoditized factory components, lower margin, more competition from Rockwell/Siemens/ABB), Safety & Productivity (tools/professional — under “strategic alternatives” review, i.e., likely to be divested), and arguably NI/Test & Measurement (a competitive, cyclical instrument market). The software moat is asserted — management’s “being right 99.9% of the time is not good enough” pitch for mission-critical, regulated, real-time industrial software is plausible — but AVEVA/Siemens are formidable and the AI thesis cuts both ways.

Verdict: a durable but narrow moat — genuine, scale-and-captivity-driven, and wide in process DCS/final-control/measurement; thinner in discrete, tools, and the contested software frontier. The moat is real enough to defend high margins and pricing; it is not wide enough, on the evidence, to justify pricing Emerson like a high-return compounder at ~5x sales.

5. Growth History and Forward Opportunities

History is dominated by the portfolio reshape, which makes reported revenue a poor guide. Reported revenue went from $16.8B (FY2020, including Climate) → $12.9B (FY2021, Climate moved to discontinued operations) → $18.0B (FY2025, rebuilt via NI + AspenTech consolidation + organic growth). The clean read is underlying (organic) growth, which has run low-to-mid single digits: management guides FY2026 to ~+3% underlying (4% ex the software-renewal timing), within a long-run algorithm of roughly mid-single-digit organic + margin expansion + capital return. This is not a fast grower; it is a steady compounder whose earnings growth comes as much from mix, margin, and buyback as from volume.

The quality of the growth is improving but mixed.

• High-quality: the software/recurring layer. ACV $1.64B growing 9–10%, high-incremental-margin, sticky. Test & Measurement +12% (semis, aerospace/defense). Ovation/power +mid-teens to +23%. These are the verticals the multiple is paying for, and they are genuinely secular.
• Lower-quality / cyclical: Discrete Automation (+1%, factory cycle), Safety & Productivity (−2%, likely to be sold), China chemicals (down mid-single-digits, overcapacity), Europe (soft). Much of the near-term “growth” is also backlog conversion and price (+3.5 pts price in Q2-FY26) rather than volume — legitimate, but not the same as unit demand acceleration.

Forward opportunities (the bull’s ledger).

1. Secular verticals. Power/grid/datacenter, LNG, life sciences (GLP-1 capacity), semis, A&D — a $11.2B funnel, 85% in these areas, with multi-year project visibility. Power is the standout (Ovation orders +41%; behind-the-meter generation for data centers).
2. Software monetization & AI. Embedding AI in AspenTech/DeltaV/Ovation/NI (“Nigel”) to move toward “autonomous operations,” with tiered pricing to capture value. Management is explicit this is not yet a meaningful revenue line — it is a 2027+ option.
3. Margin & self-help. Continued cost-out, price/cost discipline, and mix shift toward software keep adjusted segment EBITDA margins ~28% with a path higher; >40% full-year incremental leverage guided.
4. Further portfolio pruning. Divesting Safety & Productivity would push the mix even more toward high-margin automation/software (and likely support the multiple).

The bear’s qualifier. Strip the reshape, price, and backlog, and the underlying unit demand is a ~mid-single-digit grower exposed to a process-capex cycle that is mixed (strong US/power, weak China/Europe/chemicals) and to a Middle East that just cost a point of sales. The growth is real but not fast, and the secular-vertical narrative is, by construction, hard to falsify in real time — which is exactly what makes it dangerous at a peak multiple.

Verdict: medium-quality growth — a steady mid-single-digit organic compounder with a genuine, improving high-quality software/recurring layer and real secular verticals, wrapped around cyclical, geographically uneven core demand. Good, not great; and not fast enough to comfortably support a ~5x-sales multiple on its own.

6. Financial Quality

Emerson’s financial quality is high on a cash basis and mediocre on a GAAP basis, and the gap between the two is the single most important analytical fact in this name.

Margins and their trajectory (the genuine improvement). Gross margin expanded from ~41.8% (FY2020) to 52.8% (FY2025) as the low-margin Climate/InSinkErator businesses left and high-margin software/instrumentation grew. GAAP operating margin rose from ~16% to 19.6%; EBITDA margin from ~21% to 28%; adjusted segment EBITDA margin is ~28% and guided to hold. This is a real structural mix-up, not financial engineering.

Free cash flow (genuinely strong). FY2025 operating cash flow (continuing) ~$3,676M less capex of only ~$431M (2.4% of sales — an asset-light, design-and-assemble model) = reported free cash flow ~$3,245M, ~18% of sales. FY2026 is guided to $3.5–3.6B. This is high-quality, capital-light cash generation and the strongest pillar of the bull case. (Note: some data aggregators report a “free cash flow” field that equals operating cash flow and does not net capex; Emerson’s own ~$3.2–3.6B figure already nets it. Reported total-company OCF is also noisy from divestiture tax payments — ~$0.6B in FY2025, ~$2.3B in FY2023.)

The GAAP-vs-adjusted wedge (the quality-of-earnings crux).

• FY2025 GAAP diluted EPS (continuing) was $4.03; adjusted EPS was $6.00 — a $1.97 (≈49%) gap.
• The FY2025 bridge to adjusted segment EBITA ($4,693M, 26.0% of sales) adds back, pretax: intangible amortization $1,083M (of which $425M is NI-specific), restructuring $162M, acquisition/divestiture fees $277M.
• ~two-thirds of the wedge is intangible amortization. It is non-cash — so adjusted EPS is a fair proxy for cash earnings — but it is the real, recurring economic cost of the $16B+ Emerson spent on NI and AspenTech. Excluding it does not make the acquisition free; it makes the returns look better than they are. The honest scorecard: on the inflated post-deal capital base, GAAP ROE is ~5.6% and GAAP ROIC ~7.7%; even adjusted/cash ROIC is only ~10–11%.
• FY2026 guide: GAAP $4.79–4.89 → adjusted $6.45–6.55, a ~$1.4 amortization-led wedge that persists for years (the NI/AspenTech intangibles amortize over a long schedule).

Why this matters. The market quotes and pays ~23x on the adjusted $6.50 — not 37x on GAAP $4. That is defensible if and only if you believe the amortization is a sunk, non-economic accounting artifact. The counter-argument: amortization here proxies the reinvestment needed to sustain the acquired software/technology (R&D capitalized into the deals), and the all-in ~10–11% cash ROIC — barely above an ~8–9% WACC — confirms that the acquired growth was bought at roughly fair value, not at a bargain that creates a durable return premium. The legacy operating business is high-return; the assembled software business is, so far, a roughly-cost-of-capital deployment dressed in an adjusted-EPS headline.

Balance sheet. Total debt ~$13.1B; cash ~$1.5B; net debt ~$11.6B, up from $4.1B after the debt-funded AspenTech buy-in. Net debt/EBITDA ~2.3x; net-debt/net-capital ~36%; interest coverage ~8.6x — investment-grade and conservative, with capacity to keep returning capital. Goodwill ($18.2B) + other intangibles ($9.5B) = $27.7B = 66% of $42.0B total assets, and tangible common equity is negative — the balance-sheet signature of a company that has bought its current form. No impairments to date.

Verdict: economics do improve with scale on a cash/operating basis (52.8% gross margin, 18% FCF margin, light capex, high-return legacy franchises) — but GAAP returns are mediocre and even cash ROIC on the full capital base is only ~10–11%. The cash generation is excellent; the return on the capital deployed to build the new Emerson is not. Quality is real but the adjusted headline overstates how good the returns actually are.

7. Capital Allocation

Capital allocation is the most consequential — and most debatable — part of the Emerson story, because the entire current company is a capital-allocation decision.

The portfolio transformation (the big bet). Over four years management executed a decisive reshape:

• Sells (well-timed, strong prices): InSinkErator → Whirlpool $3.0B (Oct-2022); Climate Technologies/Copeland → Blackstone $14.0B enterprise value (May-2023; ~$9.7B upfront cash + a retained 40% stake later monetized for ~$1.5B + a $1.9B note, fully exited Aug-2024); plus smaller exits (Therm-O-Disc). These were lower-multiple, cyclical, lower-margin businesses sold near a cyclical high — genuinely good capital allocation on the sell side.
• Buys (decisive, but at premium multiples, debt-funded, near an automation/AI peak): National Instruments $8.2B equity (Oct-2023, ~5x sales for a business still GAAP-loss-making at the segment line); the original AspenTech combination (2022, contributing Emerson’s Heritage/SLM software + cash for a majority stake); and the AspenTech minority take-private $7.2B at $265/share (March-2025), a debt-funded purchase of the ~43% it did not own at a full SaaS valuation. Total automation/software spend $16B+.

The strategic logic — exit cyclical low-multiple hardware, build a focused high-margin automation-plus-software franchise — is coherent and the sells were excellent. The buys are where the skepticism concentrates: premium prices, debt funding, and timing into the height of automation/AI enthusiasm, with the returns case resting entirely on adjusted (amortization-excluded) earnings rather than GAAP.

Shareholder returns (steady but unremarkable).

• Dividend: a 69-consecutive-year Dividend King — one of the longest streaks in the market — but the increases are now token (~0.5–1%/yr): $2.02 (FY2021) → $2.11 (FY2025) → $2.22 (declared Nov-2025). ~$1.2B/yr. Yield ~1.5%. The streak is a marketing asset more than a capital-return engine; real cash return has shifted toward buybacks.
• Buybacks: ~$4.6B over five years ($500M FY21 @ ~$95; $500M FY22 @ ~$88; $2,000M FY23 @ ~$94; $435M FY24 @ ~$99; $1,167M FY25 @ ~$126 — i.e., the largest repurchases at the highest prices). Diluted share count fell only ~10.6M (577.3M → 566.7M, ~2%) over three years — buybacks have roughly offset SBC dilution, not meaningfully shrunk the count. FY2026 plans ~$1.0B buyback + $1.2B dividend = ~$2.2B total return (~2.6% of market cap).

Insider behavior (a quiet negative). Across 108 Form 4s over 29 months (Jan-2024 → Jun-2026), there were ZERO open-market purchases (code P). Activity was grants, tax-withholding, and 18 discretionary, NOT-10b5-1-planned sales (~$21.4M aggregate, led by CEO Karsanbhai ~$10.8M / 84,414 shares). No insider put fresh capital in across a $68→$160 double, and the selling was discretionary at a richest-ever-on-sales valuation. Not damning, but not the signal you want.

Incentive design (decent, with one real flaw). The annual bonus (formulaic) is Adjusted EPS + Operating Cash Flow; the LTI is 55% PSU / 45% RSU, with the PSU = Adjusted EPS (60%) + Cumulative FCF (40%) plus a relative-TSR modifier, three-year. The good: no volume/revenue/“empire-building” metric, and a cash-flow anchor. The flaw: there is no explicit ROIC/ROCE hurdle, and the plan is anchored on Adjusted EPS — the exact metric that excludes the >$1B/yr of M&A amortization. Management is therefore paid on the figure that flatters its own acquisition strategy and is silent on the returns that strategy actually earned. CEO total comp ~$21.3M; pay ratio ~402:1 (high); say-on-pay 89.6% (solid, not ringing).

Verdict: above-average capital allocation on the sell side and in strategic clarity; below-average on the buy side (premium, debt-funded acquisitions justified by adjusted earnings) and merely adequate on shareholder return (token dividend growth, dilution-offsetting buybacks at peak prices). Management reshaped the company intelligently but is now paid on, and markets the stock on, a metric that excludes the cost of the reshape. The jury on whether the $16B+ of automation/software M&A creates durable per-share value — rather than just a better-looking income statement — is still out, and the ~10–11% all-in cash ROIC is the early, sobering read.

8. Changes and Headwinds — Last Two Years

Strategic / structural.

• AspenTech take-private completed (March 2025) at $265/share, ~$7.2B, debt-funded — the defining recent event. Folded the former standalone AspenTech segment into “Software & Control”; net debt jumped from $4.1B to $11.6B.
• Climate/Copeland fully exited (Aug-2024) — the last leg of the conglomerate-to-pure-play transition.
• Safety & Productivity under “strategic alternatives” review — a likely future divestiture that would further concentrate the mix in automation/software.
• Board refreshment: Jennifer Newstead (Apple GC, ex-Meta CLO) elected, joining Aug-2026, expanding the board to 11.

Demand / macro headwinds.

• Middle East conflict (Q2-FY26): a real, quantified hit — Emerson has $1.2B (7% of sales) and an $8.5B installed base in the region; the conflict cost ~1 point of FY2026 sales (~$50M in Q2, ~$100M more expected), forced manufacturing shutdowns and <50% field-service activity, and the Strait of Hormuz closure disrupted component imports. Management frames it as deferred not lost, with a ~$100M rebuild/restart opportunity over ~6 quarters (and a much larger, unquantified opportunity if damaged LNG capacity is rebuilt).
• China chemical weakness: structural overcapacity in Chinese chemicals; China guided down mid-single-digits — a multi-quarter drag.
• Europe soft; automotive/discrete weak.
• Software-renewal timing depressed first-half FY2026 reported software growth/margin (~2 pts sales, ~90 bps margin) — optical, reversing.
• Tariffs: management models a net-neutral impact (IEEPA removal offset by Section 232/122 and freight), excluding any refund benefit.

Sell-side / sentiment. Bernstein initiated Outperform (6/10/26); DA Davidson initiated Neutral (6/16/26) — bracketing the bull/skeptic debate at the current price.

Net assessment. The strategic changes (AspenTech, Climate exit, S&P review) strengthen the business mix and the long-term thesis. The macro headwinds (Middle East, China, Europe) are real but largely cyclical/transitory and have already trimmed the FY2026 guide. None of these is thesis-breaking; collectively they argue that the operating story is intact while the valuation has run ahead of it.

Verdict: the changes strengthen the business and weaken nothing structurally — but they do not justify the multiple, and the headwinds (Middle East, China) confirm that even a high-quality automation franchise remains a cyclical, geographically exposed industrial.

9. Risk Analysis (Risk Matrix)

The dominant risk is valuation, not the business. Emerson is unlikely to suffer a catastrophic operating loss; it is quite likely to suffer multiple compression if organic growth stays mid-single-digit and the secular-vertical narrative fails to accelerate, because the current multiple already capitalizes the optimistic case.

10. Valuation Discussion (Embedded Expectations)

Where the multiple sits. At $150.66, Emerson trades at ~$84.8B market cap / ~$96.4B EV:

• EV/Sales ~5.3x (FY2025 $18.0B) — vs. ~2.6x in FY2020 and a ~99th-percentile own-history reading.
• EV/EBITDA ~19x (FY2025 $5.05B) — vs. ~12x FY2020; own-history high end.
• Forward P/E ~23x on adjusted EPS ~$6.50 (FY2026 guide midpoint); ~37x on trailing GAAP EPS ~$4.05; ~95th-percentile own-history P/E.
• FCF yield ~4.2% (on ~$3.55B FY2026 FCF); dividend yield ~1.5%.

Own-history vs. cross-sectional — the central valuation tension. On its own multi-year history, Emerson has never been more expensive on sales and is near its richest on earnings — the re-rating is unambiguous. Yet cross-sectionally Emerson still screens cheaper than its premium multi-industrial peers — Eaton (~28x EV/EBITDA, ~36–39x P/E), Parker (~23x, ~33x), Ametek (~22.6x, ~33–35x), Roper (software-rollup, but ~7th-pctile own-history and “cheap”) — and roughly in line with Honeywell (~17–19x) and richer than 3M (~14x). The bull leans on the cross-sectional discount (“still cheaper than the compounders”); the skeptic leans on the own-history extreme plus the structural fact that Emerson has always been the low-multiple “de-rate anchor” of the cohort for good reasons (slower organic, ~10–13% ROIC). When a perennial discount name reaches its own all-time-high multiple, the burden of proof is on permanence.

Embedded-expectations / reverse read. To justify ~5.3x EV/sales and ~23x forward adjusted earnings, the market must underwrite roughly: (a) organic growth durably accelerating from ~3% toward mid-single-digit-plus on the secular verticals; (b) adjusted segment EBITDA margins holding ~28% and edging higher; © the software/ACV layer compounding 10%+ and re-rating the whole company toward a software-blended multiple; and (d) the ~10–11% all-in cash ROIC rising as the NI/AspenTech deals season. That is an internally consistent bull case — but every leg is an extrapolation, and the dominant one (a software re-rating of the entire enterprise) capitalizes a ~$1.6B ACV layer as if it sets the multiple for an $18B mostly-hardware company. A reverse-DCF at ~8.5% WACC backs into ~5–6% perpetual FCF growth to support the current EV — achievable but with essentially no margin of safety and no discount for cyclicality.

Scenario sketch (illustrative, not a target).

• Bear (~$105–120): organic stalls to ~LSD in a process-capex/China downturn; multiple reverts toward ~16–17x EV/EBITDA / ~18x forward adjusted EPS (its own historical center and the cohort “anchor”). ~20–30% downside.
• Base (~$130–155): mid-single-digit organic + ~28% margins + ~$2.2B/yr return; multiple drifts modestly lower from the peak as growth proves steady-not-spectacular; roughly the current zone, total return ≈ FCF/dividend yield + low-single-digit growth.
• Bull (~$175–200): secular verticals (power/LNG/datacenter) accelerate organic to HSD, software/ACV re-rates the blend, S&P divestiture purifies the mix; multiple holds ~5–6x sales / ~25x+ adjusted EPS. Requires the optimistic extrapolation to substantially validate.

Verdict: the price embeds the bull case. Emerson is fairly-to-richly valued for a high-quality, mid-single-digit organic grower with ~10–11% all-in returns; the upside requires a software-led structural re-rating to continue from an already-record multiple, while the downside (multiple reversion toward its own historical center) is both larger and more probable. No price target; no recommendation — this is an embedded-expectations read, not a call.

11. Variant Perception

Consensus view. Emerson is a successfully transformed, higher-quality automation pure-play with a software kicker (AspenTech/NI), secular exposure to power/datacenter/LNG/life-sciences, ~28% margins, strong free cash flow, and a fortress dividend — a “quality compounder” deserving of a premium re-rating. Sell-side is split right at the price (Bernstein Outperform vs. DA Davidson Neutral), which is itself a tell that the easy money has been made.

Strongest bull case. The reshape is real and the sells were brilliantly timed; the core franchises (Fisher, Rosemount, DeltaV/Ovation) are genuine wide-moat, high-return, aftermarket-rich businesses; the software/ACV layer (10%+ growth, recurring, high-incremental-margin) is under-appreciated and should re-rate the blended multiple; and the secular verticals (power for AI data centers above all) give Emerson a multi-year, visible, accelerating demand backdrop that justifies paying up. On this view, ~23x adjusted earnings is reasonable for a business compounding earnings high-single-to-low-double-digits with optionality on AI-enabled “autonomous operations.”

Strongest bear case. You are paying a record multiple (~99th-pctile sales) for a low-to-mid-single-digit organic grower whose all-in cash ROIC is only ~10–11%, whose headline EPS excludes the >$1B/yr cost of the M&A that built it, whose insiders bought nothing and sold into the run, whose dividend grows ~1%/yr, and whose buybacks merely offset dilution at peak prices. Emerson is structurally the cohort’s discount name; at its own all-time-high multiple, mean-reversion risk dominates, and the “software re-rating” thesis capitalizes a $1.6B ACV layer as if it governs the whole $18B enterprise. The AI thesis is as likely to compress industrial-software seat value as to expand it.

The 3–5 assumptions that matter most:

1. Is the re-rating structural or cyclical? (Does ~5x sales persist, or revert toward the ~3–4x own-history center?)
2. Does organic growth accelerate? (Mid-single-digit forever = fairly valued; HSD+ on secular verticals = the bull; LSD in a downturn = the bear.)
3. Do the NI/AspenTech acquisitions earn above WACC over time, or stay at ~cost-of-capital, confirming the buys were fairly-priced empire-building?
4. Does AI expand or compress industrial-software economics?
5. Does the software/ACV layer grow fast enough, long enough, to genuinely re-rate the blended multiple — or is it too small relative to the hardware base?

What would falsify each side. Bull falsified by: a couple of quarters of flat/negative organic orders, ACV deceleration below high-single-digit, or a process-capex downturn that exposes the cyclicality at a 23x multiple. Bear falsified by: organic accelerating to HSD on power/datacenter, ACV sustaining 10%+ with visible AI monetization, and the S&P divestiture plus margin expansion proving the mix-up is permanent — validating the premium.

Factor-positioning read (where consensus may be offsides). The tape says this is a high-quality cyclical that has already re-rated, not a momentum freight-train and not a falling knife. FactorsToday: beta ~1.26 (Market loading ~1.06), a strong DividendYield loading (+0.66), a negative LowVolatility loading (−0.17) (i.e., it trades like a higher-vol cyclical, not a defensive), a meaningful custom “Industrial Automation Leaders” loading (+0.22) confirming the identity, and — tellingly — no Value loading and no Momentum loading. Risk-adjusted record is solid-not-spectacular (3-yr +22%/yr at 0.71 Sharpe; specific vol ~20%; R² ~0.62). The read: the market already pays Emerson as a premium automation name, the re-rate is in the price, and the absence of a value loading means no one is treating it as cheap. That supports the variant view that consensus is offsides on permanence — extrapolating a structural re-rating into a name the factor model still classifies as a dividend-paying, above-market-beta industrial that has had its run.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the normalized organic growth rate once the reshape, price (+3.5 pts), backlog conversion, and software-renewal timing are stripped out — 3%, 4%, or genuinely 5%+?
2. What return are the NI and AspenTech acquisitions actually earning on invested capital, and is it rising? (Management discloses adjusted segment margins but no deal-level ROIC.)
3. How large and how durable is the AI/“autonomous operations” monetization opportunity — a real 2027+ revenue line with pricing power, or a competitive feature race against AVEVA/Siemens?
4. Will Safety & Productivity be divested, at what multiple, and how are proceeds redeployed (buyback at peak, or more M&A)?
5. How much of the Middle East and China weakness is cyclical vs. structural (Strait of Hormuz logistics; Chinese chemical overcapacity and domestic-champion competition)?
6. Does the dividend-growth algorithm stay token (~1%/yr), implicitly conceding the cash is better spent on buybacks/M&A — and is that the right call at these buyback prices?
7. What is the company’s own through-cycle ROIC/ROCE target, given the incentive plan conspicuously omits a returns hurdle?

14. What Must Be True (Bull and Bear, with Falsification Tests)

Bull case — what must be true:

1. The software/recurring layer (ACV 10%+) compounds long enough and large enough to re-rate the blended multiple structurally — and stays ahead of AVEVA/Siemens.
2. Secular verticals (power/datacenter/LNG/life-sciences) accelerate organic growth to high-single-digit and sustain it through a cycle.
3. Adjusted segment EBITDA margins hold ~28% and edge higher, with NI/AspenTech returns rising above WACC as the deals season.
4. Capital allocation creates per-share value — S&P divested well, buybacks/M&A accretive on a cash basis.
   • Falsification test: two-to-three consecutive quarters of flat-or-negative organic orders, ACV growth dropping below high-single-digit, or adjusted segment margins slipping below ~27% — any would break the “structural re-rate” thesis and likely trigger multiple compression from the ~99th-pctile peak.

Bear case — what must be true:

1. Emerson is structurally a mid-single-digit organic grower with ~10–11% all-in returns — the cohort’s discount name — and the record multiple mean-reverts toward its own historical center (~3–4x sales / ~16–17x EV/EBITDA).
2. The acquired software business stays a ~cost-of-capital deployment flattered by adjusted EPS; AI compresses rather than expands seat economics.
3. A process-capex/China-chemical downturn exposes the cyclicality at a peak multiple.
   • Falsification test: organic growth accelerating to and holding high-single-digit on the secular verticals, ACV sustaining 10%+ with visible, priced AI monetization, and a clean, value-accretive S&P divestiture — which together would validate the premium and falsify the mean-reversion thesis.

The pivot: both cases turn on the same fact set — the durability of the software/secular re-rating versus the gravitational pull of Emerson’s structural identity as a slow-organic, ~10–11%-ROIC automation name. At ~99th-percentile-own-history valuation, the asymmetry favors the skeptic.

15. Source Appendix

See Appendix B below for the full, dated source list. Core sources: Emerson FY2021–FY2025 10-Ks (esp. emr-20250930) and FY2026 10-Qs (emr-20260331); FY2026 proxy (DEF 14A); Q2-FY2026 earnings call transcript (5-May-2026); Form 4 corpus (108 filings, Jan-2024–Jun-2026); public fundamentals/ratios data; valuation-percentile and factor-model context; 5-year price history. Peer cross-reads against public filings and disclosures for Honeywell, Roper, Ametek, Parker-Hannifin, Eaton, Johnson Controls, and 3M.

APPENDIX A — Standard Diligence Questionnaire

Supplemental to the research memo. Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company?

• Is the post-transformation re-rating (richest-ever multiple on sales) structural or a cyclical/extrapolation peak? (The central debate.)
• What return are the NI and AspenTech acquisitions actually earning — is the $16B+ automation/software spend creating per-share value, or just a better-looking adjusted income statement?
• How big and durable is the AI/“autonomous operations” software opportunity, and does AI expand or compress industrial-software economics?
• Why are insiders selling (discretionarily) and buying nothing if the software re-rating is real?
• Will Safety & Productivity be divested, and how will proceeds be redeployed?
• How exposed is Emerson to the China chemical glut and Middle East process-capex disruption?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? (Interpretation) Mid-to-high cycle. Margins are at structural highs (mix-driven, genuine), but underlying process-capex demand is uneven (strong US/power, weak China-chemicals/Europe) and the Middle East just cost a point of sales. Adjusted EPS is at a record; the multiple is at an all-time high, which is the bigger concern than the earnings level.

Driven by the external environment or internal actions? Both — internal (portfolio reshape, margin self-help, price) drove the margin/mix improvement; external (process-capex cycle, energy prices, secular power/datacenter demand) drives volume.

How stable are revenues? Moderately stable — ~65% MRO/recurring tied to a sticky installed base + $1.64B recurring software ACV provides a floor; ~35% project/cyclical adds volatility. Backlog $8.2B (+9%), book-to-bill 1.07 give near-term visibility.

Outlook for products/services? Secularly favorable in the core (automation of energy/power/life-sciences/semis); the software/AI layer is the forward growth vector. (Fact: funnel $11.2B, ACV +9–10%.)

How big will this market be — growing, shrinking, domestic or international? Global, growing low-to-mid-single-digit with secular pockets (power/datacenter, LNG, life sciences) growing faster. ~49% of sales are ex-Americas; the US is the strongest current market.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable in the DCS/instrumentation core (entrenched oligopoly: Emerson, Honeywell, Siemens, ABB, Yokogawa, Schneider); intensifying in industrial software (AVEVA/Siemens) and test (Keysight/Teradyne).

How profitable is the business (ROIC, ROE)? (Fact) GAAP ROE ~5.6%, GAAP ROIC ~7.7%, all-in cash ROIC ~10–11% on the inflated post-deal base; the legacy operating franchises earn high-teens-to-20s on tangible capital. Gross margin 52.8%, adj. segment EBITDA ~28%, FCF margin ~18%.

How profitable is the industry — competitors, barriers to entry? Profitable in the core; barriers are high (20–30yr install life, safety certification, operator trust, aftermarket lock-in). No successful new global DCS entrant in decades.

Can the business be easily understood? Yes at a high level (sensors/valves/control systems/software for process plants); the segment and GAAP-vs-adjusted accounting is complex post-M&A.

Can it be undermined by foreign low-cost labor? Largely no for the high-spec core (engineered, certified, mission-critical); discrete/components face more cost competition; China domestic champions (e.g., Supcon) are a long-term watch.

Do brands matter? Yes — Fisher, Rosemount, DeltaV, Ovation, AspenTech, NI are trusted franchise brands; trust/installed-base reputation is itself a barrier.

Nature of competition? Installed-base capture and aftermarket annuity in the core; feature/price/ecosystem competition in software and test.

Customers’ switching costs? Very high in process DCS/instrumentation (re-engineering, re-certification, downtime risk over a multi-decade asset life); lower in discrete/tools.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The installed base / aftermarket annuity and brand/relationship value are economic assets not on the balance sheet. Conversely, $27.7B of goodwill+intangibles (66% of assets) is recognized and amortizing.

Off-balance-sheet liabilities? Routine (operating leases capitalized; pension ~$0.5B net liability, modest; standard guarantees). Nothing alarming disclosed.

How conservative is the accounting? (Interpretation) GAAP is conservative (full amortization of M&A intangibles depresses reported earnings); the adjusted framing management leads with — and is paid on — is aggressive in that it excludes the >$1B/yr recurring cost of its acquisition strategy. Read both.

How CapEx-hungry is the business? Light — capex ~2.4% of sales (~$431M FY2025); asset-light design-and-assemble + software model, supporting high FCF conversion.

Capital Allocation & Management

How much FCF, and how is it used? ~$3.2B FY2025 (~18% margin), guided $3.5–3.6B FY2026. Uses: ~$1.2B dividend + ~$1.0B buyback (~$2.2B return) + M&A + deleveraging post-AspenTech.

Significant acquisitions recently? Yes — NI ($8.2B, 2023), AspenTech majority (2022) then minority take-private ($7.2B @ $265/sh, March 2025); divestitures InSinkErator ($3.0B, 2022) and Climate/Copeland ($14.0B EV, 2023, exited 2024). (Interpretation: excellent sells, premium debt-funded buys.)

Buying back shares? Yes but modestly — ~$4.6B/5yr, share count down only ~2% over three years (buybacks ~offset SBC dilution); FY2025 repurchases were the largest at the highest prices.

Issuing large amounts of stock to insiders? SBC ~$263M/yr (modest, ~1.5% of sales); buybacks roughly neutralize it.

Compensation policy of directors/management? (Fact) Bonus = Adjusted EPS + Operating Cash Flow; LTI = 55% PSU (Adj EPS 60% + Cumulative FCF 40% + rel-TSR modifier) / 45% RSU. No volume metric (good); no ROIC hurdle and anchored on adjusted EPS that excludes M&A amortization (flaw). CEO ~$21.3M, pay ratio ~402:1, say-on-pay 89.6%.

Motivations of management? (Interpretation) Strategically focused and execution-strong (the reshape was decisive); but incentives reward adjusted EPS / the acquisition strategy without a returns hurdle — and zero insider open-market buying suggests no personal conviction at the current price.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — US common stock, NYSE, standard 1099 dividend. Not an ADR/MLP/K-1.

Dividend policy? 69-consecutive-year increaser (“Dividend King”); yield ~1.5%; payout ~34% of adjusted EPS (~54% of GAAP); increases now token (~0.5–1%/yr).

How profitable is the business? See ROIC/margins above — high margins, light capex, strong FCF; mediocre GAAP and ~10–11% all-in cash returns.

Is net income diverging from cash from operations? Cash flow exceeds GAAP net income (D&A/amortization > capex; the amortization wedge means cash earnings > GAAP earnings) — a favorable divergence on a cash basis, but it is also what makes the adjusted-vs-GAAP gap so large.

Risks & Downside

What factors would cause the stock to decline? Multiple de-rating from the ~99th-pctile-own-history peak (the dominant risk); a process-capex/China-chemical downturn; ACV/software deceleration; evidence the NI/AspenTech deals stay at ~cost-of-capital; Middle East escalation; broad industrial/market drawdown (beta ~1.26).

Risk of a catastrophic loss? Low — diversified blue-chip, IG balance sheet (net debt/EBITDA ~2.3x), 69-yr dividend, no going-concern or fraud-risk profile.

Chance of a total loss? Very low. The realistic risk is opportunity cost / drawdown from a rich entry, not impairment.

Recent News & Events

Has the business environment changed recently? Yes — Middle East conflict (1-pt FY26 sales drag, Strait of Hormuz logistics), China chemical weakness (guided down MSD), Europe soft; offset by US strength and surging power/datacenter orders.

Significant acquisitions/divestitures? AspenTech take-private completed (March 2025); Climate/Copeland fully exited (Aug 2024); Safety & Productivity under strategic-alternatives review.

Change in accounting policies? Segment realignment post-AspenTech (former standalone AspenTech segment folded into “Software & Control,” prior periods restated). No restatement of substance.

Recent changes — new markets, facilities, management? Board refresh (Jennifer Newstead, Apple GC, joining Aug-2026); continued capacity investment for power/LNG/semis verticals; new sell-side initiations (Bernstein Outperform 6/10/26; DA Davidson Neutral 6/16/26).

APPENDIX B — Source Appendix

Report date: 2026-06-19. Primary sources first. Fact / Interpretation / Assumption / Open Question distinctions are maintained in the memo body; this appendix lists the underlying sources. All financial figures reconciled to SEC filings where possible; third-party data aggregators used for ratios/percentiles/factor data and cross-checked.

Primary — SEC filings

1. Emerson FY2025 Form 10-K — emr-20250930.htm, filed 2025-11-10 (CIK 0000032604). Revenue, segment detail (Intelligent Devices / Software & Control), GAAP-vs-adjusted reconciliation, intangible amortization, balance sheet (goodwill/intangibles, net debt), capex/FCF, geography.
2. Emerson FY2021–FY2024 Form 10-Ks — emr-20210930 / 20220930 / 20230930 / 20240930. Multi-year trend; portfolio-transformation accounting (Climate/Copeland & InSinkErator discontinued ops; NI & AspenTech purchase accounting).
3. Emerson Q2-FY2026 Form 10-Q — emr-20260331.htm, filed 2026-05-05. Latest quarter financials, raised FY2026 guidance, Middle East impact, net debt.
4. Emerson Q1-FY2026 Form 10-Q — emr-20251231.htm, filed 2026-02-03.
5. Emerson FY2026 Proxy (DEF 14A) — executive compensation (bonus = Adjusted EPS + OCF; LTI PSU = Adj EPS 60% + Cumulative FCF 40% + rel-TSR modifier), CEO pay (~$21.3M) and pay ratio (~402:1), say-on-pay (89.6%), board.
6. Form 4 corpus — 108 filings, Jan-2024 → Jun-2026 (via EDGAR). Zero open-market purchases (code P); 18 discretionary (non-10b5-1) sales (~$21.4M; CEO Karsanbhai ~$10.8M).
7. 8-K material-event filings — portfolio transactions, earnings releases, AspenTech take-private close (March 2025), board changes.

Primary — Company disclosures & transcripts

8. Q2-FY2026 earnings call transcript — 5-May-2026 (company webcast/transcript). CEO Lal Karsanbhai, CFO Mike Baughman, COO Ram Krishnan. Orders +5%, backlog $8.2B (+9%), book-to-bill 1.07, ACV $1.64B (+9%), project funnel $11.2B, growth verticals +22% (power +23%, Ovation orders +41%), FY2026 guide (sales +4.5%, adj EPS $6.45–6.55, FCF $3.5–3.6B, return ~$2.2B), Middle East and China commentary, AI/software framing.
9. Emerson investor relations — segment definitions, growth-vertical disclosures, capital-return framework (referenced via transcript and filings).

Secondary — Quantitative aggregators (cross-checked to filings)

10. Aggregated fundamentals data — income statement, balance sheet, cash flow, profitability ratios (ROE/ROA/ROIC/margins), enterprise value, valuation multiples, per-share data (FY2020–FY2025, multi-period). Used for ratio trends and EV; reconciled to 10-K.
11. Own-history valuation-percentile data — own-history percentile ranks: P/E 34.8x (94.7th pctile), P/B 4.18x (53.5th), P/S 4.64x (98.99th), composite 82.4th; price $150.66 (6/18/26). Own-history context only.
12. 5-year daily price history — daily adjusted OHLCV, EMAs, beta/alpha. 5yr low $67.93 (9/27/22), high $160.42 (2/10/26); 52w range $122.75–$160.42; EMAs ~$142/$140/$136.
13. Financial news — recent items (DA Davidson Neutral initiation 6/16/26; Bernstein Outperform initiation 6/10/26; macro/sector items). Quiet tape.
14. FactorsToday factor model — loadings (Market ~1.06, DividendYield +0.66, LowVolatility −0.17, “Industrial Automation Leaders” +0.22; no Value/Momentum), beta 1.26, R² ~0.62, specific vol ~19.9%, leaderboard (3yr +22%/yr, Sharpe 0.71; lifetime max drawdown ~−56%), related-stocks (ITT, ITW, PH, DOV).

Secondary — Peer cross-reads (public filings)

15. Honeywell, Siemens, ABB, Schneider, Yokogawa public filings/disclosures — process-automation/DCS competitive structure and the multi-industrial valuation cohort.
16. Roper Technologies public filings — software-rollup capital-allocation / cash-ROIC comparison.
17. Ametek, Parker-Hannifin, Eaton, Johnson Controls, 3M public filings — multi-industrial peer multiples, ROIC/margins, valuation reads.

Analytical frameworks

18. Competition Demystified (Greenwald & Kahn) — moat-type taxonomy (customer captivity + economies of scale), market-share-stability and ROIC tests applied to the DCS/instrumentation core vs. discrete/software periphery.
19. Capital Returns (Marathon/Chancellor) — supply-side capital-cycle lens on the secular-vertical demand narrative at a peak multiple.

Notes on data quality / reconciliation

• GAAP vs adjusted: the memo distinguishes GAAP diluted EPS (cont.) $4.03 from adjusted $6.00 (FY2025) and FY2026 adjusted guide $6.45–6.55; ~⅔ of the wedge is intangible amortization (NI/AspenTech). All multiples specify which basis.
• Some aggregator “free cash flow” fields equal operating cash flow (does NOT net capex); the memo uses Emerson’s own reported FCF (~$3.2B FY2025) which already nets ~$431M capex.
• Net debt rose $4.1B→$11.6B FY2024→FY2025 from the debt-funded AspenTech minority buy-in (minority interest $5.87B→$16M).
• No ownership position is implied or assumed.